Oh really, well I think Leo "astounding results" and Fox Chase may differ from your opinion. But nothing in life is guaranteed.
I think we have an antibiotic platform that is SPECIAL, I continue to accumulate, who really knows, you make your bet and either you make a lot of money or you don't.
Infinity - u may be right. Gram neg compounds farther away, though Boucher in her gram neg IDSA article characterized as "insufficient evidence" in reference to B, i.e. as in TBD. And recall the push for pathogen-specific agents... More targeted drugs getting to mkt sooner. (See article below)
That said, your posts inc come across to me as leading/loaded ... Me beginning to Q ur backstory and motives. More than just playing Devils Advocate. Maybe I'm wrong. Hope so as you come across as informed. I learn from you. Brilacidin has a lot going for it as does the larger platform even if the Fox Chase work will take more time. It can be a mini-blockbuster all on its own.
Anyway, I came across another PYMX poster that whets the appetite. Milan 2011 ECMIDD. Hopefully the April presentation on gram-neg work in Copenhagen will have updates.
News 
Market Data 
Discover 
AI
